Working Each Day As If People’s Lives Depend on Us

At CSL Behring, a Job Isn’t Just a Job

Recruitment #4
(Photo by Patrick Fore)

By Elizabeth Walker

December 14, 2016

I’m often asked, “What makes CSL Behring a great place to work?” For me, it’s about our patient centricity and company purpose. We develop and deliver innovative specialty biotherapies, helping people with life-threatening conditions live full lives. That’s an inspiring responsibility. Our CEO Paul Perreault encourages us to work each day as if people’s lives depend on us ‒ because they do. I can’t think of a better reason for coming to work every day.

Continue reading


What Will Healthcare Look Like in 50 to 100 Years?

If we focus on innovation and sustainability, healthcare will evolve in ways that are in sync with the changing needs of patients, the economy and global politics.

BioFest 2016

The following post is excerpted from Paul Perreault’s remarks at International BioFest 2016 in Melbourne, Australia.

December 6, 2016

Healthcare statisticians tell us that the first person who will live to 150 years of age has already been born. Considering human biology and the challenges we would need to overcome, doubling our life expectancy at first seems fanciful. But with our understanding of science and the refined art of personalized medicine, 150 may be reasonable.

In fact, our understanding of human biology is expanding at an exponential rate. Ten years ago it took the world’s greatest minds 10 years to map the human genome. Now it takes one day. Even for those of us in the healthcare sector, it is virtually impossible to predict what healthcare will look like in 50 or 100 years. But there are constants to guide us.

Continue reading


Free Trade Helps Drive Innovation

March 19, 2015

By Anthony Farina

Paul Perreault, John-Berry, Niels Marquardt

Left to right: AMCHAM CEO Niels Marquardt, CSL Limited CEO and Managing Partner Paul Perreault, and U.S. Ambassador to Australia John Berry at Opportunity Australia 2015 in Philadelphia.

The U.S.-Australia Free Trade Agreement (FTA) has fostered substantial international trade in the ten years since it was forged between the two countries. The FTA is particularly significant for life sciences companies such as CSL Behring because it provides greatly expanded markets for products and patient care, and helps drive innovation.

The FTA is particularly significant for life sciences companies such as CSL Behring

Some of the policies covered in the FTA that sustain investments in innovation were highlighted today at Opportunity Australia 2015. The event was held in Philadelphia to mark the tenth anniversary of the agreement. John Berry, U.S. Ambassador to Australia participated in the event, which was hosted by the American Chamber of Commerce in Australia.
Continue reading

Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring.
This site is not intended as a forum for discussing CSL Behring or other companies' products.
Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.